Enveric Biosciences (ENVB) Other Non Operating Income (2016 - 2025)
Enveric Biosciences (ENVB) posted Other Non Operating Income of $6628.0 for Q4 2025, up 1163.88% sequentially from -$623.0 in Q3 2024.
Enveric Biosciences (ENVB) Other Non Operating Income (2016 - 2025) Analysis & Trends
Enveric Biosciences has reported Other Non Operating Income for 8 years, with the latest figure at $6628.0 in Q4 2025.
- Quarterly Other Non Operating Income changed N/A year-over-year to $6628.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6005.0 (changed N/A YoY) and the FY2025 annual result came in at $9193.0, changed N/A from the prior year.
- Other Non Operating Income rose to $6628.0 in Q4 2025 per ENVB's latest filing, from -$623.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $714000.0 in Q2 2023 and troughed at -$231000.0 in Q3 2022.
- A 4-year average of $58286.4 and a median of -$623.0 in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 1447.17% in 2023, down 1447.17% in 2023.
- Over 4 years, Other Non Operating Income stood at -$41000.0 in 2022, then jumped by 1841.46% to $714000.0 in 2023, then sank by 100.09% to -$623.0 in 2024, then jumped by 1163.88% to $6628.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $6628.0, -$623.0, and $714000.0 for Q4 2025, Q3 2024, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6,628.00 |
| Sep 30, 2024 | -623.00 |
| Jun 30, 2023 | 714,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | -41,000.00 |
| Sep 30, 2022 | -231,000.00 |
| Jun 30, 2022 | -53,000.00 |
| Dec 31, 2019 | 27,759.00 |
| Sep 30, 2019 | -9.00 |
| Jun 30, 2019 | 4,566.00 |
| Dec 31, 2018 | -3.49 Mn |
| Sep 30, 2018 | 75,747.00 |
| Jun 30, 2018 | 1,790.00 |
| Mar 31, 2018 | 6,199.00 |
| Dec 31, 2017 | -16,926.00 |
| Sep 30, 2017 | 17,446.00 |
| Jun 30, 2017 | 8,624.00 |
| Mar 31, 2017 | -4,149.00 |
| Dec 31, 2016 | 214,283.00 |
| Sep 30, 2016 | -195,518.00 |